14 December 2015: Articles
Lambl’s Excrescence Associated with Cryptogenic Stroke: A Case Report and Literature Review
Challenging differential diagnosis, Unusual setting of medical care, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Andrew Chu BCDEF , Thu Thu Aung BCDF , Haim Sahalon CDE , Vivek Choksi EF , Hamid Feiz EDOI: 10.12659/AJCR.895456
Am J Case Rep 2015; 16:876-881
Abstract
BACKGROUND: In 1856, a Bohemian physician, Vilém Dušan Lambl, first described the presence of filiform lesions in aortic valve leaflets. Lambl’s excrescences are tiny filiform strands that arise on the line of valve closure, and result from valvular wear and tear. It is a rare cause of cardioembolic stroke that can be detected by transesophageal echocardiogram.
CASE REPORT: We encountered a 51-year-old, African-American woman with a history of recurrent strokes that we suspect may be the result of Lambl’s excrescence. The patient was treated with dual antiplatelet therapy and was recommended to have surveillance transesophageal echocardiograms at 6 months and 1 year from the time of discharge.
CONCLUSIONS: As there are no definitive guidelines for the management of patients with Lambl’s excrescences, we present a review of the current medical literature and a specific case report in an attempt to provide a better strategy for managing this condition. In our case report, we focus on the management and treatment for Lambl’s excrescence because no clear evidence has been published in the literature. Our review indicates that Lambl’s excrescence, despite its relative scarcity, should be considered in the differential diagnosis of a patient with cryptogenic stroke.
Keywords: Aortic Valve - ultrasonography, Echocardiography, Transesophageal, Heart Valve Diseases - ultrasonography, Ischemic Attack, Transient - etiology, Magnetic Resonance Imaging, Platelet Aggregation Inhibitors - therapeutic use
Background
In 1856, Vilém Dušan Lambl, a Bohemian physician first described the presence of filiform lesions on aortic valve leaflets [1]. Lambl’s excrescences (LEs) are found on the line of closure of heart valves, and can result in mechanical endothelial damage. This condition is most often diagnosed incidentally by transesophageal echocardiogram (TEE) [2]. They carry a potential risk of embolizing to distant organs causing stroke [3–6] or myocardial infarction [7,8]. Histologically, they are composed of fibroelastic and hyalinized stroma covered by a layer of endothelial cell lining [3]. They are similar histopathologically to cardiac papillary fibroelastomas (CPFs). They differ in that CPFs are larger and are found away from the line of valve closure, whereas LEs are found at the line of valve closure [9].
Although the most common causes of cardioembolic stroke include atrial fibrillation, valvular heart disease, patent foramen ovale, and left ventricular dysfunction [10], LE is not commonly considered in the list of potential causes of stroke. LEs are hypothesized to form as a result of valvular wear and tear. Once formed, they can be a source of microthrombi [10]. Since the first description of LE involving the aortic valve in 1856, only several cases have been reported in the medical literature. An evidence-based approach to the management and treatment of LE has yet to be elucidated. We report a case of a 51-year-old woman with a history of 2 prior cerebral vascular accidents, who presented to the emergency department with transient ischemic attack (TIA) symptoms.
Case Report
A 51-year-old, right-handed, African-American woman presented to the emergency room with transient symptoms of worsening baseline left-sided weakness and slurred speech. Her past medical history was significant for well-controlled hyper-tension for 11 years, 2 ischemic strokes, and the presence of LE on the aortic valve on TEE. She was also a former tobacco abuser prior to February 2013. A review of her medical record revealed 2 prior hospitalizations. During her first hospitalization in February 2013, the patient was admitted for an ischemic stroke. Brain magnetic resonance imaging (MRI) showed multiple areas of acute ischemia, including the right corona radiata and centrum semiovale, with multiple foci of acute ischemia in the gray-white matter interface on the right hemisphere (Figures 1, 2). Her medical workup included an electrocardiogram (EKG), carotid Doppler, and transthoracic echo-cardiogram (TTE) with bubble study, all of which were negative. Aortography and 4-vessel cerebral angiography done did not show atherosclerotic plaque or occlusive disease. Her lipid profile showed total cholesterol 142 mg/dL, low-density lipoprotein (LDL) 83 mg/dL, high-density lipoprotein (HDL) 36 mg/dL, and triglyceride 114 mg/dL. She was diagnosed with a cryptogenic stroke and was discharged home with aspirin 81 mg daily and pravastatin 40 mg daily. Subsequently, the patient underwent outpatient cardiac monitoring with an implantable loop recorder, which did not reveal cardiac arrhythmia. During her second hospitalization 3 months later (May 2013), the patient presented with a transient episode of left-sided weakness and slurred speech. An MRI brain with diffusion revealed a resolving old ischemic infarct with new areas of punctate acute ischemia in the posterior supratentorial brain at the level of the centrum semiovale (Figure 3). TEE at that time revealed a 2-mm wavy strand on the aortic valve protruding into the ascending aorta, suggestive of an LE. There was no evidence of valvular vegetation (Figures 4, 5). The left atrium was normal in size, and no thrombus was detected in the left atrium or left atrial appendage. She was discharged home and instructed to take aspirin 81 mg daily and clopidogrel 75 mg daily.
The patient returned to the emergency department several months later with similar symptoms of transient left-sided weakness. It was noted that the patient was not compliant with the dual antiplatelet therapy in the prior month. Her symptoms resolved upon initial evaluation. She scored 2 points on the NIH Stroke Scale. On physical examination her vital signs were stable and the neurological examination was consistent with diminished strength intensity of 4/5 in both proximal and distal left upper and lower extremities. This was consistent with her baseline motor function. All her laboratory values were normal, including a lipid panel, hypercoagulability workup, and troponins. Bilateral carotid Doppler ultrasonography showed a stable carotid plaque in the common carotids with no evidence of a hemodynamically significant stenosis on either side. MRI of the brain showed improvement of her prior ischemic strokes, but no evidence of a new ischemic event. TTE did not show any potential cardioembolic source. Since the MRI failed to reveal any focal finding, the multidisciplinary team decided to resume dual antiplatelet therapy with aspirin 81 mg daily and clopidogrel 75 mg daily.
At her 3-month and 6-month follow-up visits, the patient had no further neurological events to suggest ongoing thromboembolic risk. Her symptoms of left-sided weakness remained essentially unchanged. The patient reported compliance with her medications during this time period. She also had a repeat TEE at 6 months, which showed a stable size LE. We advised the patient to continue with lifelong dual antiplatelet therapy and to repeat TEE in 12 months to evaluate the stability of the LE.
Discussion
Only several cases of LE have been reported in the medical literature. We performed a review of published literature using PubMed to identify previously published cases of LE from 1981 up to 2014 (Table 1) [2–6,8,11–24]. Aortic and mitral valves were the two most common locations of LE. However, ischemic events were more commonly observed in association with LEs on aortic valves [3,5,6,8,15–17,20,21,23,24] as compared to mitral valves [4,13]. Although there has been some case reports on giant LEs (≥2 cm in diameter) associated with ischemic stroke [6,15], no clear evidence exists in the literature showing the correlation between the strand size and potential risk of thromboembolic event.
Whether LEs are involved in generating ischemic events remains controversial. In the only prospective study in our review, Roldan et al. [25] performed TEE assessment on healthy volunteers (Group 1: n=88), patients without suspected cardioembolic disease (Group 2: n=88) and patients undergoing TEE for suspected cardioembolic disease (Group 3: n=49). They found a similar prevalence of valve excrescences across all groups, suggesting that excrescences were not associated with cardioembolic phenomenon. This was further supported by their observation that the rate of cardioembolic events over approximately >4 years was similar in those with and without valve excrescences. Additionally, they noted that aspirin and warfarin therapy did not seem to affect the prevalence or natural history of valve excrescences. However, due to the relatively small sample size, low event rates, and lack of histological confirmation of the type of excrescence, the authors were unable to definitively exclude LE as a possible source of cardioembolic events. Their findings are in contrast to those of Freedberg et al., who noted, in a retrospective analysis, a higher prevalence of excrescences in patients with embolic phenomenon than those without (10.6%
Given the lack of consensus in literature, it is difficult to exclude LEs as a possible source of embolic phenomenon in patients with cryptogenic stroke. In our case, alternative causes were ruled out (negative EKG, hypercoagulability panel, carotid US, and arrhythmias), leading us to suggest that LEs may have been responsible for our patient’s presentation. This is in line with previous case reports documenting a similar association [3,4–6,13,15–17,21,23,24]. However, for our patient, the first episode of stroke was diagnosed as cryptogenic stroke and no TEE workup was done at that time. Therefore, we could not conclude that her stroke was associated with an undiagnosed LE. During her second episode of stroke, an LE was found on TEE and she was started on dual antiplatelet therapy. During the last hospitalization, our patient was diagnosed with TIA as there was no evidence of an infarct on brain MRI. Although our patient’s CHA2DS2-VASc score was 4, there was no evidence of atrial fibrillation revealed from her loop recorder. Therefore, we decided to instruct the patient to continue with dual antiplatelet therapy (aspirin 81 mg and clopidogrel 75 mg daily) since she had failed aspirin alone in the past. In the event our patient was to develop atrial fibrillation, switching from dual antiplatelet to anticoagulation therapy and excision of LE would be considered. We recommended our patient to have a surveillance TEE at 6 months and 1 year from the time of hospital discharge to visualize the stability of LE.
Conclusions
Further research is needed to evaluate the clinical importance of LE, including the pathophysiology, its association with ischemic events, and how to manage and treat it. It is our opinion that physicians should still consider LE in the differential diagnosis for a patient with cryptogenic stroke until conclusive evidence suggests otherwise. We recommend performing a TEE in this population, and if LE is present, we suggest that treatment with dual antiplatelet therapy should be considered. If there is a recurrent ischemic event while on this therapy, a trial of anticoagulation therapy should be considered before proceeding with surgical resection of the LE. Indication for the surgical resection of LE is still controversial, simply based on a few case reports [3,4,8,11,13–15,19,21,22] and poor follow-up outcomes. In conclusion, our case is in line with previous case reports; however, this underscores the need for well-designed studies to determine appropriate strategies for treating valve excrescences in these patients.
References:
1.. Lambl V, Papillare excrescenzen an der semilunar-klappe der aorta: Wien Med Wochenschr, 1856; 6; 1 [in German]
2.. Voros S, Nanda NC, Thakur AC, Lambl’s excrescences (valvular strands): Echocardiography, 1999; 16; 399-414, pmid: 11175169
3.. Aziz F, Baciewicz FA, Lambl’s excrescences: review and recommendations: Tex Heart Inst J, 2007; 34; 366-68, pmid: 17948090
4.. Al-ansari S, Hindori V, Riezebos RK, Yilmaz A, Multiple Lambl’s excrescences with subvalvular extension, a rare cause of cryptogenic stroke: treated by port-access cardiac surgery: BMJ Case Rep, 2013; 2013 pii: bcr2013201161
5.. Kalavakunta JK, Peddi P, Bantu V, Lambl’s excrescences: a rare cause of stroke: J Heart Valve Dis, 2010; 19; 669-70, pmid: 21053748
6.. Wu TY, Gerber IL, Roxburgh RH, Thrombo-embolic cerebral infarction secondary to giant Lambl’s excrescence: J Clin Neurosci, 2013; 20; 1632-34, pmid: 23669170
7.. Dangas G, Dailey-sterling FG, Sharma SK, Non-Q-wave infarction and ostial left coronary obstruction due to giant Lambl’s excrescences of the aortic valve: Circulation, 1999; 99; 1919-21, pmid: 10199892
8.. Quinson P, De gevigney G, Boucher F, [Fibrous aortic valve tumor (Lambl’s excrescence) trapped in the right coronary artery. Apropos of a case]: Arch Mal Coeur Vaiss, 1996; 89; 1419-23, pmid: 9092401 [in French]
9.. Boone SA, Campagna M, Walley VM, Lambl’s excrescences and papillary fibroelastomas: are they different?: Can J Cardiol, 1992; 8; 372-76, pmid: 1617520
10.. Leary MC, Caplan LR, Cardioembolic stroke: An update on etiology, diagnosis and management: Ann Indian Acad Neurol, 2008; 11(1); 52-55, pmid: 19966981
11.. Cha SD, Incarvito J, Fernandez J, Giant Lambl’s excrescences of papillary muscle and aortic valve: echocardiographic, angiographic, and pathologic findings: Clin Cardiol, 1981; 4; 51-54, pmid: 7226592
12.. Fitzgerald D, Gaffney P, Dervan P, Giant Lambl’s excrescence presenting as a peripheral embolus: Chest, 1982; 81; 516-17, pmid: 7067520
13.. Nighoghossian N, Trouillas P, Perinetti M, [Lambl’s excrescence: an uncommon cause of cerebral embolism]: Rev Neurol (Paris), 1995; 151; 583-85, pmid: 8594653 [in French]
14.. Berent R, Hartl P, Rossoll M, Punzengruber C, [Lambl’s excrescence as tumorous heart valve mass]: Dtsch Med Wochenschr, 1998; 123; 423-26, pmid: 9581169 [in German]
15.. Aggarwal A, Leavitt BJ, Images in clinical medicine. Giant Lambl’s excrescences: N Engl J Med, 2003; 349; e24, pmid: 14681522
16.. Wolf RC, Spiess J, Huber R, [Lambl’s excrescence and cerebral ischemic insult]: Nervenarzt, 2006; 77; 1492-94, pmid: 17102989 [in German]
17.. Siles rubio JR, Ruiz de castroviejo del campo J, Tirado miranda R, [Transient ischemic attack due to Lambl’s excrescence. Report of a case and review of the literature]: An Med Interna, 2006; 23; 181-83, pmid: 16796413 [in Spanish]
18.. Jaffe W, Figueredo VM, An example of Lambl’s excrescences by transesophageal echocardiogram: a commonly misinterpreted lesion: Echocardiography, 2007; 24; 1086-89, pmid: 18001363
19.. Nakahira J, Sawai T, Katsumata T, Lambl’s excrescence on aortic valve detected by transesophageal echocardiography: Anesth Analg, 2008; 106; 1639-40, pmid: 18499592
20.. Mito M, Kiyuna M, Toda T, [A rare case report of incarceration of Lambl’s excrescence of aortic valve resulting in myocardial infarction]: Rinsho Byori, 2012; 60; 758-61, pmid: 23198535 [in Japanese]
21.. Liu RZ, Yu SY, Li Y, Migraine-like headache and ischemic strokes in two patients with Lambl’s excrescences: Chin Med J (Engl), 2012; 125; 3346-48, pmid: 22964336
22.. Morgan JA, Paone G, Resection of Lambl’s excrescence on the aortic valve in a patient with rheumatic mitral valve disease and a left atrial thrombus: Heart Surg Forum, 2012; 15; E215-17, pmid: 22917827
23.. Yacoub HA, Walsh AL, Pineda CC, Cardioembolic stroke secondary to Lambl’s excrescence on the aortic valve: a case report: J Vasc Interv Neurol, 2014; 7; 23-25, pmid: 25298855
24.. Davogustto G, Fernando RR, Loghin C, Lambl’s excrescence, migrainous headaches, and “tiger stripes”: puzzling findings in one patient: Tex Heart Inst J, 2015; 42; 70-72, pmid: 25873805
25.. Roldan CA, Shively BK, Crawford MH, Valve excrescences: prevalence, evolution and risk for cardioembolism: J Am Coll Cardiol, 1997; 30; 1308-14, pmid: 9350932
26.. Freedberg RS, Goodkin GM, Perez JL, Valve strands are strongly associated with systemic embolization: a transesophageal echocardiographic study: J Am Coll Cardiol, 1995; 26; 1709-12, pmid: 7594107
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






